Skip to main content

July 2025, Vol 15, No 7

Advances in technology, including artificial intelligence and telemedicine platforms, offer promising avenues to support precision oncology efforts remotely. Read More ›

The Department of Veterans Affairs has been able to “dramatically increase” clinical trial opportunities and participation over the past 2 years, thanks in part to a joint initiative from the Prostate Cancer Foundation and Veterans Affairs,... Read More ›

Access to treatment and survival outcomes among US veterans with stage I non–small cell lung cancer may vary depending on demographic and sociological patterns,... Read More ›

The phase 3 DeLLphi-304 study evaluated tarlatamab, a bispecific T-cell engager immunotherapy, versus chemotherapy in patients with small cell lung cancer that progressed on or after platinum-based chemotherapy. Read More ›

The phase 3 IMforte study evaluated the efficacy and safety of first-line maintenance treatment with lurbinectedin combined with atezolizumab versus atezolizumab alone in patients with extensive-stage small cell lung cancer. Read More ›

Nurses and navigators, especially those embedded in community programs, can help bridge the access gap by promoting education, building trust, and facilitating access early in the patient journey. Read More ›

The phase 3 S2302 Pragmatica-Lung study offers a new blueprint for cancer clinical trials, one that emphasizes simplification, inclusivity, and real-world applicability, according to Konstantin Dragnev, MD, of Dartmouth Cancer Center. Read More ›

Minority populations remain underrepresented in cancer clinical trials, undermining understanding of therapeutic efficacy, safety, and biomarker relevance in these groups, while also significantly limiting the broader applicability of clinical trial findings. Read More ›


It’s important to recognize and celebrate the pivotal role front desk professionals play in transforming patient care. Read More ›